Search
Metastatic Colorectal Cancer Clinical Trials
A listing of 22 Metastatic Colorectal Cancer clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
13 - 22 of 22
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Metastatic Colorectal Cancer
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
There are currently 22 active clinical trials seeking participants for Metastatic Colorectal Cancer research studies. The states with the highest number of trials for Metastatic Colorectal Cancer participants are California, Florida, Texas and New York.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Study
Recruiting
Are you tired of living with chronic cough? The ASPIRE Study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough. You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you.
Conditions:
Chronic Cough
Refractory or Unexplained Chronic Cough
Cough
Asthma
Allergic Asthma
Featured Trial
Studying an Investigational Virus Vaccine
Recruiting
The main objectives of this study are to assess the safety and effectiveness of an investigational vaccine aimed at preventing norovirus, commonly known as the stomach flu. Participants will be randomly assigned to receive either the investigational vaccine or a placebo. Should you express interest, you will be contacted directly by the research site, which will provide further details and answer any questions you may have about study requirements, risks/benefits, and any compensation.
Conditions:
Healthy
Interested in vaccine studies
All Conditions
Preventative Trials
Featured Trial
Evaluating an Investigational Treatment for Hidradenitis Suppurativa
Recruiting
The main objectives of this Phase 2 study are to evaluate the safety and effectiveness of an investigational medication in adults with moderate to severe hidradenitis suppurativa (HS), a chronic skin condition. Participants will be randomly assigned to receive the investigational treatment or a placebo. Should you express interest, the research site will contact you directly to provide further details and address any questions you may have about study requirements, risks/benefits, and compensation.
Conditions:
All Conditions
Hidradenitis suppurativa (Skin disorder)
Dermatology
A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations
Recruiting
To learn if the drug combination of adagrasib, cetuximab, and cemiplimab can help to control metastatic CRC with KRAS G12C mutations.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/13/2025
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts +1 locations
Conditions: Metastatic Colorectal Cancer, KRAS G12C Mutations
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
Recruiting
This is a First-in-Human Phase IA/IB/II open label dose escalation study of intravenous (IV) administration of ONC-392, a humanized anti-CTLA4 IgG1 monoclonal antibody, as single agent and in combination with pembrolizumab in participants with advanced or metastatic solid tumors and non-small cell lung cancers.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/30/2025
Locations: Highlands Oncology Group, Springdale, Arkansas +36 locations
Conditions: Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Colorectal Cancer, Sarcomas, Metastatic Prostate Cancer, Ovarian Cancer, Small Cell Lung Cancer, Metastatic Breast Cancer, Pancreas Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Cervical Cancer, Adenoid Cystic Carcinoma, Salivary Gland Cancer, Urothelial Carcinoma
Couple-Based Mindfulness Intervention for Metastatic Colorectal Cancer
Recruiting
The overall objective of this study is to develop a novel couple-based mindfulness intervention aimed at reducing distress in patients with metastatic colorectal cancer (mCRC) and their partners.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
01/09/2025
Locations: University of Colorado Cancer Center, Aurora, Colorado
Conditions: Metastatic Colorectal Cancer
Study of Onvansertib in Combination with FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants with a KRAS or NRAS Mutation
Recruiting
The purpose of this study is to assess 2 different doses of onvansertib to select the lowest dose that is maximally effective, and to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of onvansertib in combination with FOLFIRI + bevacizumab or FOLFOX + bevacizumab in patients with KRAS or NRAS-mutated metastatic colorectal cancer (CRC) in the first-line setting.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/04/2024
Locations: Mayo Clinic - Arizona, Phoenix, Arizona +40 locations
Conditions: Metastatic Colorectal Cancer, CRC, KRAS/NRAS Mutation
Pressure-enabled Delivery in Radioembolization (TriNav Study)
Recruiting
The purpose of the study is to determine if the type of catheter used in the mapping procedure prior to radioembolization improves the delivery of radioactivity to tumor(s) in participants with liver cancer.
The name of the devices involved in this study are:
* Pressure Enabled Drug Delivery (PEDD)/TriNav Infusion System
* Standard 2.4F microcatheter, not otherwise specified
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/18/2024
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts +1 locations
Conditions: Liver Cancer, Hepatocellular Carcinoma, Metastatic Colorectal Cancer
Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination with Cetuximab and Encorafenib in Patients with Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy
Recruiting
To find the recommended dose of ulixertinib that can be given in combination with cetuximab and/or encorafenib to patients with unresectable/metastatic CRC and who have received EGFR or BRAF-directed therapy in the past.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/16/2024
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Metastatic Colorectal Cancer
Exercise for Gut Microbiome in Patients With Young-Onset Colorectal Cancer Undergoing Chemotherapy: The COURAGE Trial
Recruiting
This research study is a randomized controlled trial that will observe changes in microbiome activity, changes in chemotherapy toxicity, and any changes in treatment outcomes between two groups of participants undergoing chemotherapy with either early-stage or metastatic colorectal cancer.
The names of the study groups involved in this study are:
* Exercise
* Waitlist Control
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
07/22/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Colorectal Cancer, Metastatic Colon Cancer, Metastatic Colorectal Cancer
Immunotherapy for Third Line Metastatic Colorectal Cancer
Recruiting
This is a Phase IIB multi-site, open label study of a next generation immunotherapy for third-line MSI-S metastatic colorectal cancer using an "off-the-shelf", non-genetically manipulated living immune cell product (AlloStim) derived from the blood of healthy donors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/09/2024
Locations: Mt. Sinai Comprehensive Cancer Center, Miami Beach, Florida +3 locations
Conditions: Metastatic Colorectal Cancer
Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer
Recruiting
This study is being done to see if combining liposomal irinotecan with TAS102 and bevacizumab confers clinical benefit for patients with treatment refractory metastatic colorectal cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/20/2024
Locations: University of Wisconsin Carbone Cancer Center, Madison, Wisconsin
Conditions: Metastatic Colorectal Cancer
Dabrafenib + Trametinib + PDR001 In Colorectal Cancer
Recruiting
This research study is studying a combination of drugs as a possible treatment for metastatic colorectal cancer characterized by BRAF V600E mutation.
The names of the study drugs involved in this study are:
Dabrafenib
Trametinib
PDR001
Gender:
All
Ages:
18 years and above
Trial Updated:
06/24/2022
Locations: Massachusetts General Hosital Cancer Center, Boston, Massachusetts +1 locations
Conditions: Metastatic Colorectal Cancer
13 - 22 of 22